Register for real-time alerts, custom portfolio, and market movers
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| NeuBase Therapeutics Inc | NBSE | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 0.4333 | 04:49:26 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 0.4333 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 0.39 - 4.80 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 0.4333 | USD |
NeuBase Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 1.6M | 3.73M | - | 0 | -33.78M | -9.06 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
NeuBase Therapeutics News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical NBSE Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.415 | 0.4485 | 0.40 | 0.4250254 | 74,835 | 0.0183 | 4.41% |
| 1 Month | 0.4251 | 0.4653 | 0.39 | 0.4288249 | 83,052 | 0.0082 | 1.93% |
| 3 Months | 0.6916 | 1.15 | 0.39 | 0.7566588 | 246,666 | -0.2583 | -37.35% |
| 6 Months | 0.67 | 1.51 | 0.39 | 0.8575642 | 294,614 | -0.2367 | -35.33% |
| 1 Year | 2.746 | 4.80 | 0.39 | 1.92 | 814,061 | -2.31 | -84.22% |
| 3 Years | 114.60 | 132.00 | 0.39 | 14.10 | 403,768 | -114.17 | -99.62% |
| 5 Years | 90.00 | 257.80 | 0.39 | 49.39 | 332,434 | -89.57 | -99.52% |
NeuBase Therapeutics Description
| NeuBase Therapeutics Inc is a pre-clinical stage biopharmaceutical company. It is engaged in the development of gene silencing therapies with its synthetic antisense oligonucleotides. Its Patrol platform is focused on the development of drugs for rare genetic diseases such as Huntington's Disease, Myotonic Dystrophy and Familial Parkinson's Disease among others. |
